Skip to main content

Summary

for people ages 18 years and up (full criteria)
at San Francisco, California and other locations
study started
estimated completion:

Description

Summary

A prospective, phased-pivotal, international randomized trial to evaluate the effectiveness of the OCS™ Liver to preserve and assess donor livers intended for transplantation.

Official Title

International Randomized Trial to Evaluate The Effectiveness of The Portable Organ Care System (OCS™) Liver For Preserving and Assessing Donor Livers for Transplantation (OCS Liver PROTECT Trial)

Keywords

Liver Transplantation Liver Preservation for Transplant Liver Extracts

Eligibility

You can join if…

Open to people ages 18 years and up

  • Registered male or female primary Liver transplant candidate
  • Age ≥18 years old
  • Signed: 1) written informed consent document and 2) authorization to use and disclose protected health information

You CAN'T join if...

  • Acute, fulminant liver failure
  • Prior solid organ or bone marrow transplant
  • Chronic use of hemodialysis or diagnosis of chronic renal failure, defined as chronic serum creatinine of >3 mg/dl for >2 weeks and/or requiring hemodialysis
  • Multi-organ transplant
  • Ventilator dependent
  • Dependent on > 1 IV inotrope to maintain hemodynamics

Locations

  • University of California San Francisco accepting new patients
    San Francisco, California, United States
  • University of Washington accepting new patients
    Seattle, Washington, 98195, United States
  • University of Texas Southwest accepting new patients
    Dallas, Texas, 75390, United States
  • Houston Methodist accepting new patients
    Houston, Texas, 77030, United States
  • University of Minnesota accepting new patients
    Minneapolis, Minnesota, 55455, United States
  • Henry Ford Hospital accepting new patients
    Detroit, Michigan, 48202, United States
  • Emory accepting new patients
    Atlanta, Georgia, 30322, United States
  • Massachusetts General Hospital accepting new patients
    Boston, Massachusetts, 02114, United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
TransMedics
ID
NCT02522871
Lead Scientist
Chris Freise
Study Type
Interventional
Last Updated
May 1, 2018
I’m interested in this study!